ANVS Annovis Bio Inc.

25.57
+0.27  (+1%)
Previous Close 25.3
Open 24.91
52 Week Low 2.418
52 Week High 35
Market Cap $176,589,923
Shares 6,906,137
Float 4,335,877
Enterprise Value $185,774,333
Volume 132,785
Av. Daily Volume 271,121
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
ANVS401
Alzheimer’s disease (AD) and Parkinson’s disease (PD)
Phase 2
Phase 2
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
ANVS401
Alzheimer’s disease
Phase 2a
Phase 2a
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Latest News

  1. BERWYN, Pa., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE:ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced that Maria Maccecchini, Ph.D., Founder and Chief Executive Officer, will present at the BIO CEO & Digital Conference, available online February 16-18, 2021. Annovis Bio's presentation will be accessible on demand during the virtual event for all registered attendees.

    Event registration is available at https://www.bio.org/events/bio-ceo-investor-digital-conference

    About Annovis Bio

    Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc. (Annovis) is a clinical-stage, drug platform company addressing neurodegeneration…

    BERWYN, Pa., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE:ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced that Maria Maccecchini, Ph.D., Founder and Chief Executive Officer, will present at the BIO CEO & Digital Conference, available online February 16-18, 2021. Annovis Bio's presentation will be accessible on demand during the virtual event for all registered attendees.

    Event registration is available at https://www.bio.org/events/bio-ceo-investor-digital-conference

    About Annovis Bio

    Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc. (Annovis) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease (AD), Parkinson's disease (PD) and Alzheimer's in Down Syndrome (AD-DS). We believe that we are the only company developing a drug for AD, PD and AD-DS that inhibits more than one neurotoxic protein and, thereby, improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. We expect our treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. We have two ongoing Phase 2a studies: one in AD patients and one in both AD and PD patients. For more information on Annovis, please visit the company's website: www.annovisbio.com.

    Forward-Looking Statements

    Statements in this press release contain "forward-looking statements" that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "expect," "believe," "will," "may," "should," "estimate," "project," "outlook," "forecast" or other similar words, and include, without limitation, statements regarding the timing, effectiveness and anticipated results of ANVS401 clinical trials and the approval of any allowances or additional patents. Forward-looking statements are based on Annovis Bio, Inc.'s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including the risk that additional patent allowances may not be received. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled "Risk Factors" in the Annual Report on Form 10-K for the year ended December 31, 2019 filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Annovis Bio, Inc. undertakes no duty to update such information except as required under applicable law.

    Investor Relations:

    Dave Gentry, CEO

    RedChip Companies Inc.

    407-491-4498

    SOURCE: Annovis Bio, Inc.



    Primary Logo

    View Full Article Hide Full Article
  2. Berwyn, Pennsylvania--(Newsfile Corp. - February 4, 2021) - Annovis Bio Inc. (NYSE:ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced the European Patent Office (EPO) granted the Company's patent for a method of treating acute nerve and brain injuries by administering ANVS405 after the injury.

    "This new patent, covering acute indications, joins our two patents covering our primary disease targets, AD and PD, which both originate from a patent family that claims ANVS401 for the treatment of neurodegenerative diseases," commented Maria Maccecchini, Ph.D., CEO of Annovis. "While Europe has allowed the whole acute injury patent, the US Patent…

    Berwyn, Pennsylvania--(Newsfile Corp. - February 4, 2021) - Annovis Bio Inc. (NYSE:ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced the European Patent Office (EPO) granted the Company's patent for a method of treating acute nerve and brain injuries by administering ANVS405 after the injury.

    "This new patent, covering acute indications, joins our two patents covering our primary disease targets, AD and PD, which both originate from a patent family that claims ANVS401 for the treatment of neurodegenerative diseases," commented Maria Maccecchini, Ph.D., CEO of Annovis. "While Europe has allowed the whole acute injury patent, the US Patent and Trademark Office (USPTO) has asked us to split the original application into a number of patents, each one covering individual diseases that our drug targets. Therefore, we have filed divisional applications for traumatic brain injury, stroke, and spinal cord injury. We expect to receive additional patent allowances in the future, and we will continue to provide further updates as we execute on this process."

    The USPTO approved the Company's first PD patent (US 10,383,851) in August 2019. The EPO approved Annovis Bio's first AD patent (EP 2683242) on March 12, 2020. The EPO approved Annovis Bio's first acute patent (EP 3334425B1), which provides intellectual property protections through 2036, on December 16, 2020.

    ANVS401 and ANVS405 can work in chronic and acute indications because nerve cells die by the same mechanism in these diseases. ANVS401 and ANVS405 stop the toxic cascade leading to nerve cell death. Capitalizing on that knowledge, Annovis Bio is conducting two Phase 2 studies to show in both AD and PD patient populations that what was demonstrated in animals can be reproduced in humans and that ANVS401 protects the nerve cells from dying, and by doing so, preserves the associated function.

    About Annovis Bio

    Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc. (Annovis) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease (AD), Parkinson's disease (PD) and Alzheimer's in Down Syndrome (AD-DS). We believe that we are the only company developing a drug for AD, PD and AD-DS that inhibits more than one neurotoxic protein and, thereby, improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. We expect our treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. We have two ongoing Phase 2a studies: one in AD patients and one in both AD and PD patients. For more information on Annovis, please visit the company's website: www.annovisbio.com.

    Forward-Looking Statements

    Statements in this press release contain "forward-looking statements" that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "expect," "believe," "will," "may," "should," "estimate," "project," "outlook," "forecast" or other similar words, and include, without limitation, statements regarding the timing, effectiveness and anticipated results of ANVS401 clinical trials and the approval of any allowances or additional patents. Forward-looking statements are based on Annovis Bio, Inc.'s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including the risk that additional patent allowances may not be received. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled "Risk Factors" in the Annual Report on Form 10-K for the year ended December 31, 2019 filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Annovis Bio, Inc. undertakes no duty to update such information except as required under applicable law.

    Investor Relations:

    Dave Gentry, CEO
    RedChip Companies Inc.
    407-491-4498

    SOURCE: Annovis Bio Inc.

    To view the source version of this press release, please visit https://www.newsfilecorp.com/release/73661

    View Full Article Hide Full Article
  3. Berwyn, Pennsylvania--(Newsfile Corp. - February 2, 2021) - Annovis Bio Inc. (NYSE:ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced study data showing that a combination treatment using the Company's lead candidate ANVS401 and pifithrin-α (PFT-α) after stroke improved mice locomotor activity and cognitive function more so than treatment with just one or the other agent.

    The published study, "Sequential combined Treatment of Pifithrin-α and Posiphen Enhances Neurogenesis and Functional Recovery After Stroke," was conducted by Yu "Agnes" Luo, MD, Associate Professor, Department of Neurological Surgery, School of Medicine at Case Western…

    Berwyn, Pennsylvania--(Newsfile Corp. - February 2, 2021) - Annovis Bio Inc. (NYSE:ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced study data showing that a combination treatment using the Company's lead candidate ANVS401 and pifithrin-α (PFT-α) after stroke improved mice locomotor activity and cognitive function more so than treatment with just one or the other agent.

    The published study, "Sequential combined Treatment of Pifithrin-α and Posiphen Enhances Neurogenesis and Functional Recovery After Stroke," was conducted by Yu "Agnes" Luo, MD, Associate Professor, Department of Neurological Surgery, School of Medicine at Case Western Reserve University in Cleveland, Ohio.

    The study challenged mice with MCAo-induced stroke (middle carotid artery occlusion induced stoke) and after four weeks, the number of surviving neurons was quantified and the locomotor function, behavior, and cognition of the mice were evaluated.

    While both treatments yielded improvements in locomotor and cognitive function, the combined ANVS401/PFT-α treatment proved able to enhance stroke-induced endogenous neurogenesis and improve the functional recovery in stroke animals. The combined treatment also significantly improved cognitive function more than the single treatment with PFT-α alone.

    "This study adds another animal model of neurodegenerative disorders to our existing panel of animal models," commented Maria Maccecchini, Ph.D., CEO of Annovis Bio. "To date we have shown that ANVS401 fully recovers memory and learning in animals with Alzheimer's disease, Down syndrome and traumatic brain injury, fully recovers function in animals with Parkinson's disease and frontotemporal dementia, and recovers sight in rats with glaucoma. In this study we have found that our drug fully recovers cognition and function in stroke mice. Each successful study further supports our plans to move into late-stage studies of ANVS401."

    About Annovis Bio

    Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc. (Annovis) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease (AD), Parkinson's disease (PD) and Alzheimer's in Down Syndrome (AD-DS). We believe that we are the only company developing a drug for AD, PD and AD-DS that inhibits more than one neurotoxic protein and, thereby, improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. We expect our treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. We have two ongoing Phase 2a studies: one in AD patients and one in both AD and PD patients. For more information on Annovis, please visit the company's website: www.annovisbio.com.

    Forward-Looking Statements

    Statements in this press release contain "forward-looking statements" that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "expect," "believe," "will," "may," "should," "estimate," "project," "outlook," "forecast" or other similar words, and include, without limitation, statements regarding the timing, effectiveness and anticipated results of ANVS401 clinical trials. Forward-looking statements are based on Annovis Bio, Inc.'s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate, including that clinical trials may be delayed. These and other risks and uncertainties are described more fully in the section titled "Risk Factors" in the Annual Report on Form 10-K for the year ended December 31, 2019 filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Annovis Bio, Inc. undertakes no duty to update such information except as required under applicable law.

    Investor Relations:

    Dave Gentry, CEO
    RedChip Companies Inc.
    407-491-4498

    SOURCE: Annovis Bio, Inc.

    To view the source version of this press release, please visit https://www.newsfilecorp.com/release/73425

    View Full Article Hide Full Article
  4. Berwyn, Pennsylvania--(Newsfile Corp. - January 5, 2021) -  Annovis Bio Inc. (NYSE:ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced its CEO, Maria Maccecchini, Ph.D., will present at the H.C. Wainwright BioConnect Virtual Conference, taking place January 11-14, 2021.

    The on-demand presentation will be available beginning January 11 at 6:00 a.m. EST and can be accessed through the registration link.

    Dr. Maccecchini's presentation will highlight the Company's unique approach to neurodegeneration, current development pipeline, and near-term milestones.

    About Annovis Bio

    Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc. (Annovis…

    Berwyn, Pennsylvania--(Newsfile Corp. - January 5, 2021) -  Annovis Bio Inc. (NYSE:ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced its CEO, Maria Maccecchini, Ph.D., will present at the H.C. Wainwright BioConnect Virtual Conference, taking place January 11-14, 2021.

    The on-demand presentation will be available beginning January 11 at 6:00 a.m. EST and can be accessed through the registration link.

    Dr. Maccecchini's presentation will highlight the Company's unique approach to neurodegeneration, current development pipeline, and near-term milestones.

    About Annovis Bio

    Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc. (Annovis) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease (AD), Parkinson's disease (PD) and Alzheimer's in Down Syndrome (AD-DS). We believe that we are the only company developing a drug for AD, PD and AD-DS that inhibits more than one neurotoxic protein and, thereby, improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. We expect our treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. We have two ongoing Phase 2a studies: one in AD patients and one in both AD and PD patients. For more information on Annovis, please visit the company's website: www.annovisbio.com.

    Forward-Looking Statements

    Statements in this press release contain "forward-looking statements" that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "expect," "believe," "will," "may," "should," "estimate," "project," "outlook," "forecast" or other similar words, and include, without limitation, statements regarding the timing, effectiveness and anticipated results of ANVS401 clinical trials. Forward-looking statements are based on Annovis Bio, Inc.'s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate, including that clinical trials may be delayed. These and other risks and uncertainties are described more fully in the section titled "Risk Factors" in the Annual Report on Form 10-K for the year ended December 31, 2019 filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Annovis Bio, Inc. undertakes no duty to update such information except as required under applicable law.

    Investor Relations:

    Dave Gentry, CEO
    RedChip Companies Inc.
    407-491-4498

    SOURCE: Annovis Bio, Inc.

    To view the source version of this press release, please visit https://www.newsfilecorp.com/release/71383

    View Full Article Hide Full Article
  5. BERWYN, Pa., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE:ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced an interview with its CEO, Maria Maccecchini, Ph.D., will air on The RedChip Money Report television program. The RedChip Money Report airs in 100 million homes on Sundays at 6 p.m. local time in every country in Europe on Bloomberg International.

    In the exclusive interview, Dr. Maccecchini discusses the Company's unique approach to AD and other neurodegenerative diseases, current clinical trials underway, and upcoming milestones.

    To view the interview segment, please visit: https://youtu.be/GVakTzykHYg

    "The…

    BERWYN, Pa., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE:ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced an interview with its CEO, Maria Maccecchini, Ph.D., will air on The RedChip Money Report television program. The RedChip Money Report airs in 100 million homes on Sundays at 6 p.m. local time in every country in Europe on Bloomberg International.

    In the exclusive interview, Dr. Maccecchini discusses the Company's unique approach to AD and other neurodegenerative diseases, current clinical trials underway, and upcoming milestones.

    To view the interview segment, please visit: https://youtu.be/GVakTzykHYg

    "The RedChip Money Report" delivers insightful commentary on small cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies.

    About Annovis Bio

    Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc. (Annovis) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease (AD), Parkinson's disease (PD) and Alzheimer's in Down Syndrome (AD-DS). We believe that we are the only company developing a drug for AD, PD and AD-DS that inhibits more than one neurotoxic protein and, thereby, improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. We expect our treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. We have an ongoing Phase 2a study in AD patients and have commenced a second Phase 2a study in AD and PD patients. For more information on Annovis, please visit the company's website: www.annovisbio.com.

    Forward-Looking Statements

    Statements in this press release contain "forward-looking statements" that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "expect," "believe," "will," "may," "should," "estimate," "project," "outlook," "forecast" or other similar words, and include, without limitation, statements regarding the timing, effectiveness and anticipated results of ANVS401 clinical trials. Forward-looking statements are based on Annovis Bio, Inc.'s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate, including that clinical trials may be delayed. These and other risks and uncertainties are described more fully in the section titled "Risk Factors" in the Annual Report on Form 10-K for the year ended December 31, 2019 filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Annovis Bio, Inc. undertakes no duty to update such information except as required under applicable law.

    Investor Relations:

    Dave Gentry, CEO

    RedChip Companies Inc.

    407-491-4498

    SOURCE: Annovis Bio, Inc.



    Primary Logo

    View Full Article Hide Full Article
View All Annovis Bio Inc. News